Piper Sandler says BridgeBio still has juice

Another thumbs-up from the analyst crowd

Piper Sandler didn’t exactly reinvent the wheel here — it simply reiterated an Overweight rating on BridgeBio Pharma and left its $111 price target untouched. Translation: the firm still thinks the stock has more room to run, even after BridgeBio has already climbed to around $76.75.

Why you should care

Analyst calls aren’t the whole story, but they can act like a fresh coat of paint on a stock’s bull case. When a name like BridgeBio gets a renewed stamp of approval, it can help keep investor sentiment from getting wobbly — especially if the market was looking for a reason to question the valuation.

The numbers do the talking

Here’s the quick math in plain English:

• Piper’s target implies a meaningful upside cushion from current trading levels
• Wall Street’s broader target range is still pretty wide, from $80 to $157
• That spread tells you investors are still arguing over how big BridgeBio’s story really is

Big picture

This isn’t a flashy new drug-data headline or a make-or-break regulatory event. But it is a reminder that some analysts still see BridgeBio as a name with legs. In biotech, that kind of confidence can matter — because sometimes the market needs a little nudge to remember the upside story isn’t dead just because the chart got choppy.